Senseonics Holdings, Inc. (NYSE:SENS) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in shares of Senseonics Holdings, Inc. (NYSE:SENS) by 9.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,339,698 shares of the company’s stock after purchasing an additional 274,842 shares during the period. Charles Schwab Investment Management Inc. owned 0.56% of Senseonics worth $1,748,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC boosted its stake in Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after purchasing an additional 167,970 shares in the last quarter. Ridgecrest Wealth Partners LLC acquired a new position in Senseonics during the 4th quarter valued at approximately $60,000. Finally, Geode Capital Management LLC raised its holdings in shares of Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after buying an additional 179,103 shares during the last quarter. Hedge funds and other institutional investors own 12.36% of the company’s stock.

Senseonics Stock Performance

SENS opened at $0.68 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. Senseonics Holdings, Inc. has a 12-month low of $0.25 and a 12-month high of $1.40. The firm has a 50 day moving average of $0.88 and a two-hundred day moving average of $0.57. The firm has a market capitalization of $440.33 million, a PE ratio of -5.20 and a beta of 1.17.

Senseonics (NYSE:SENS) last issued its earnings results on Monday, March 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same quarter in the previous year, the firm posted ($0.07) EPS. On average, analysts anticipate that Senseonics Holdings, Inc. will post -0.14 EPS for the current year.

Wall Street Analysts Forecast Growth

SENS has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Senseonics in a report on Wednesday, March 5th. StockNews.com assumed coverage on Senseonics in a research note on Thursday, December 26th. They set a “sell” rating on the stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.